Regulus Therapeutics Inc (NASDAQ:RGLS) shares were down 5.3% during mid-day trading on Thursday . The company traded as low as $1.05 and last traded at $1.08. Approximately 641,891 shares changed hands during mid-day trading, an increase of 28% from the average daily volume of 503,349 shares. The stock had previously closed at $1.14.

A number of research analysts have recently issued reports on RGLS shares. Zacks Investment Research downgraded shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 11th. Wedbush reiterated a “hold” rating and set a $2.00 target price on shares of Regulus Therapeutics in a research report on Tuesday, October 9th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, November 6th. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $1.30.

The stock has a market cap of $10.06 million, a PE ratio of -0.09 and a beta of 2.12.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.25) by $0.07. Regulus Therapeutics had a negative net margin of 75,823.62% and a negative return on equity of 311.60%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. On average, analysts forecast that Regulus Therapeutics Inc will post -5.86 earnings per share for the current year.

In related news, Director Stelios Papadopoulos bought 50,000 shares of the company’s stock in a transaction that occurred on Saturday, December 28th. The shares were bought at an average price of $1.09 per share, for a total transaction of $54,500.00. Following the transaction, the director now directly owns 835,073 shares of the company’s stock, valued at $910,229.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have purchased a total of 173,501 shares of company stock worth $177,420 in the last quarter. 5.40% of the stock is owned by corporate insiders.

An institutional investor recently raised its position in Regulus Therapeutics stock. Renaissance Technologies LLC raised its holdings in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) by 396.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 595,501 shares of the biopharmaceutical company’s stock after purchasing an additional 475,512 shares during the quarter. Renaissance Technologies LLC owned 6.82% of Regulus Therapeutics worth $118,000 as of its most recent SEC filing.

TRADEMARK VIOLATION NOTICE: “Regulus Therapeutics (RGLS) Stock Price Down 5.3%” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/regulus-therapeutics-rgls-stock-price-down-5-3/2753523.html.

Regulus Therapeutics Company Profile (NASDAQ:RGLS)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

See Also: What is the float in trading stocks?

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.